Company: DVAX
Filing Date: 2025-04-15
Form Type: PRER14A
Source: 0000930413-25-001254
Chunk: 71

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-04-15
Form: PRER14A
Chunk 71
---
 consideration each of the goals identified and the level of completion in making an overall determination of
goal achievement for each category.

2024 Corporate Goals and Achievements.
For 2024, our corporate strategy focused on three strategic priorities: (i) Drive growth in HEPLISAV-B [Hepatitis B Vaccine (Recombinant),
Adjuvanted], (ii) Advance our differentiated pipeline programs into clinical trial initiations and data readouts; and (iii) Identify
strategic opportunities to accelerate growth, while maintaining a disciplined allocation of capital aligned with corporate strategy
to deliver long-term value through internal and external innovation.

Accordingly, our corporate goals were designed
to further build on these pillars and to help strengthen our overall financial position, our organizational capabilities and our
culture. After its consideration of the Company’s performance, as more specifically described in the following chart, the
Compensation Committee rated our overall 2024 corporate goal achievement at 102.5%.

| Corporate Goal                                         | Weight* | Corporate Achievement                                                                                                | Corporate   
 Achievement 
 Percentage  | Overall     
 Weighted    
 Achievement |
| Drive HEPLISAV-B Growth                                
 •                                                      
 Achieve U.S. Sales target of $275 million (30%).       
 •                                                      
 Achieve fourth quarter total U.S. market share greater 
 than 47% (15%).                                        | 45%     | The Compensation Committee determined that we achieved the goals in this category at an overall                      
 percentage of 89%. In determining this percentage, the Compensation Committee considered several factors, including: 
 •                                                                                                                    
 HEPLISAV-B net sales of $268 million, a 26% increase over                                                            
 prior year. (assessed 95%)                                                                                           
 •                                                                                                                    
 Fourth quarter market share of 44% compares to 42% for                                                               
 the prior year. (assessed 77%)                                                                                       
 •                                                                                                                    
 (assessed 89% overall)                                                                                               | 89%         | 40%         |

| 53 |

| Corporate                                                                                       
 Goal                                                                                            | Weight* | Corporate                                                                                                             
 Achievement                                                                                                           | Corporate   
 Achievement 
 Percentage  | Overall     
 Weighted    
 Achievement |
| Advance our existing pipeline                                                                   
 •                                                                                               
 Shingles/Zoster-02 first patient                                                                
 in during Q2 (5%).                                                                              
 •                                                                                               
 Tdap-03 study first patient in by Q3 (5%).                                                      
 •                                                                                               
 Plague-01 results in by Q3 and complete database lock                                           
 (5